Mutations in the CEP290 gene caused a frequent form of LCA, and a CRISPR–Cas9-based gene therapy to correct this mutation called EDIT-101 was evaluated in a pre-clinical study. This evidence concerns the gene CEP290 and Leber congenital amaurosis.